Stay updated on PD-L1+ NSCLC Camrelizumab + Famitinib Clinical Trial

Sign up to get notified when there's something new on the PD-L1+ NSCLC Camrelizumab + Famitinib Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the PD-L1+ NSCLC Camrelizumab + Famitinib Clinical Trial page

  1. Check
    6 days ago
    No Change Detected
  2. Check
    13 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.11 to version 2.16.12.
    Difference
    0.3%
    Check dated 2025-08-17T01:37:46.000Z thumbnail image
  3. Check
    20 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.10 to version 2.16.11.
    Difference
    0.3%
    Check dated 2025-08-09T23:59:44.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    The web page has been updated to version 2.16.10, and a previous service alert regarding planned maintenance has been removed.
    Difference
    4%
    Check dated 2025-08-02T18:19:45.000Z thumbnail image
  5. Check
    35 days ago
    Change Detected
    Summary
    The web page has been updated to reflect a new version, changing from Revision v2.16.6 to v2.16.8, and it now includes information about HHS Vulnerability Disclosure.
    Difference
    0.8%
    Check dated 2025-07-26T14:26:43.000Z thumbnail image
  6. Check
    42 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.5 to version 2.16.6.
    Difference
    0.3%
    Check dated 2025-07-19T11:20:43.000Z thumbnail image
  7. Check
    49 days ago
    Change Detected
    Summary
    A service alert has been added indicating planned maintenance starting July 25th, during which most services will be unavailable for over 24 hours.
    Difference
    4%
    Check dated 2025-07-12T07:35:48.000Z thumbnail image

Stay in the know with updates to PD-L1+ NSCLC Camrelizumab + Famitinib Clinical Trial

Enter your email address, and we'll notify you when there's something new on the PD-L1+ NSCLC Camrelizumab + Famitinib Clinical Trial page.